Jiaxing Fab New Sky Pharmaceutical Technology

Jiaxing Fab New Sky Pharmaceutical Technology is a clinical-stage biotechnology company specializing in the development of innovative radiopharmaceuticals for oncology. The company focuses on the theranostics approach, combining diagnostic imaging agents with targeted radionuclide therapies to provide precision medicine for cancer patients. Their lead programs target prostate-specific membrane antigen (PSMA) for prostate cancer and fibroblast activation protein (FAP) for a variety of solid tumors. Based in Jiaxing, China, the company leverages advanced nuclear medicine technology to develop both diagnostic PET tracers and therapeutic isotopes like Lutetium-177. The firm has established significant manufacturing and R&D infrastructure to support the full lifecycle of radiopharmaceutical development.